<DOC>
	<DOC>NCT01871805</DOC>
	<brief_summary>This non-randomized, open-label, multicenter study will evaluate the safety and efficacy of CH5424802/RO5424802 in patients with ALK-rearranged non-small cell lung cancer who failed crizotinib treatment. In Phase I, cohorts of patients will receive escalating doses of CH5424802/RO5424802 orally twice daily. In Phase II, patients who failed crizotinib treatment will receive the recommended phase II dose (600 mg) daily in two oral doses.</brief_summary>
	<brief_title>A Study of CH5424802/RO5424802 in Patients With ALK-Rearranged Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<criteria>Adult patients, &gt;/= 18 years of age Histologically confirmed, locally advanced, not amenable to curative therapy, or metastatic nonsmall cell lung cancer (NSCLC) ALKrearrangement confirmed by FDA approved test NSCLC that has failed crizotinib treatment Measurable disease as defined by RECIST v1.1 Eastern Cooperative Oncology Group (ECOG) performance status &lt;/= 2 Adequate hematologic, hepatic and renal function Prior therapy with ALK inhibitor other than crizotinib Brain or leptomeningeal metastases that are symptomatic and/or requiring treatment History of serious cardiac dysfunction History of or current active infection with hepatitis B, hepatitis C or HIV Clinically significant gastrointestinal abnormality that would affect absorption of the drug Pregnant or lactating women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>